-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gastric cancer (GC) is the third most common cause of cancer-related death in the world and the third most common cause of cancer-related death in China
Gastric cancer (GC) is the third most common cause of cancer-related death in the world and the third most common cause of cancer-related death in China
The EVIDENCE study is a prospective, multi-center, non-interventional registration study that evaluates the safety and efficacy of trastuzumab in 5 cohorts of gastric cancer patients in China, divided according to HER2 status and trastuzumab treatment Layer
The EVIDENCE study is a prospective, multi-center, non-interventional registration study that evaluates the safety and efficacy of trastuzumab in 5 cohorts of gastric cancer patients in China, divided according to HER2 status and trastuzumab treatment Layer
OS1 is defined as the time from the first diagnosis of recurrence or metastasis to death from any cause; first-line OS2 is defined as the time from trastuzumab treatment to death from any cause; second-line or third-line OS2 is defined as the first-line or second-line progression to death from any cause Time
Cohorts I, II, and IV included 174, 113, and 422 patients, respectively
In cohorts I, II, and IV, the median overall survival (OS1) of first-line treatment was 22.
OS
The first-line progression-free survival (PFS1) of cohorts I, II, and IV were 8.
The first-line progression-free survival (PFS1) of cohorts I, II, and IV were 8.
PFS
The first-line response rate (RR) of cohort I, II, and IV were 51.
The first-line response rate (RR) of cohort I, II, and IV were 51.
RR
In the first-line median OS1 (hazard ratio [HR], 0.
In the first-line median OS1 (hazard ratio [HR], 0.
Trastuzumab-related adverse reactions, grade 3-5 adverse reactions, serious adverse reactions, and death-causing adverse reactions accounted for 23.
6%, 3.
4%, 2.
3%, and 0.
6% of cohort I patients, respectively
.
In summary, the safety is consistent with the known safety of trastuzumab and chemotherapy; trastuzumab treatment improves the prognosis of patients
.
This study provides real-world data on first-line trastuzumab combined with chemotherapy in the treatment of HER2-positive mGC patients in China
.
.
This study provides real-world data on first-line trastuzumab combined with chemotherapy in the treatment of HER2-positive mGC patients in China
.
The safety is consistent with the known safety of trastuzumab and chemotherapy; trastuzumab treatment improves the prognosis of patients
.
This study provides real-world data on first-line trastuzumab combined with chemotherapy in the treatment of HER2-positive mGC patients in China
.
The safety is consistent with the known safety of trastuzumab and chemotherapy; trastuzumab treatment improves the prognosis of patients
.
This study provides real-world data on first-line trastuzumab combined with chemotherapy in the treatment of HER2-positive mGC patients in China
.
Original source:
Original source:S HUKUI Q IN, J IAFU JI, R UI -H UA XU, et al.
Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).
The Oncologist 2021;26:1–14 HUKUI Q IN, J IAFU JI, R UI -H UA XU, et al.
Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).
The Oncologist 2021;26:1–14
Leave a message here